FDA Adverse Event Malfunction Summary report: N

SYNCARDIA 70CC TAH-T

MDR report key: 7260150 · Received February 9, 2018

Report

Report Number
3003761017-2018-00038
Event Type
Malfunction
Date Received
February 9, 2018
Date of Event
January 13, 2018
Report Date
January 13, 2018
Manufacturer
SYNCARDIA SYSTEMS, LLC
Product Code
LOZ
PMA / PMN Number
P030011
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
GM
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 0

THE TAH-T CANNULA WAS NOT RETURNED TO SYNCARDIA FOR EVALUATION AS THE TAH-T REMAINS IMPLANTED. REVIEW OF THE PHOTO SUBMITTED BY THE CUSTOMER CONFIRMED THE REPORTED DARKENED, DISCOLORED CANNULAE. IT IS LIKELY THAT THE DARKENING OF THE CANNULAE RESULTED FROM EXPOSURE TO ENVIRONMENTAL FACTORS IN THE PATIENT'S SURROUNDINGS OR FROM THE AGE OF THE MATERIAL. THIS PATTERN IS CONSISTENT WITH PREVIOUSLY-REPORTED INSTANCES OF DARKENED CANNULA. THE ROOT CAUSE OF THE DARKENED CANNULAE CANNOT BE CONCLUSIVELY DETERMINED, BUT APPEARS TO BE CONSISTENT WITH THE CANNULAE DISCOLORATION INVESTIGATED IN PREVIOUSLY WITH OTHER PATIENTS. THE FREEDOM DRIVER SYSTEM OPERATOR MANUAL (F-900012-DE) AND THE FREEDOM DRIVER SYSTEM GUIDEBOOK FOR PATIENTS AND CAREGIVERS (F-900015-DE) INSTRUCT PATIENTS TO EXAMINE THEIR CANNULAE REGULARLY AND TO NOT USE CLEANERS ON THE DRIVELINES, CANNULAE, DRIVERS OR DRIVER ACCESSORIES. USERS ARE TO USE EXTREME CARE WHEN CLEANING THE FREEDOM DRIVER AND DRIVELINES, AND TO WIPE THE DRIVELINES GENTLY WITH A SOFT, CLEAN CLOTH LIGHTLY DAMPENED ONLY WITH WATER. THIS ISSUE WILL CONTINUE TO BE MONITORED AND TRENDED AS PART OF THE CUSTOMER EXPERIENCE PROCESS. SYNCARDIA HAS COMPLETED ITS EVALUATION OF THIS COMPLAINT AND IS CLOSING THIS FILE. (B)(4) FOLLOW-UP REPORT 1.

Additional Manufacturer Narrative · 0

THE TAH-T CANNULA WAS NOT RETURNED TO SYNCARDIA FOR EVALUATION AS THE TAH-T REMAINS IMPLANTED. REVIEW OF THE PHOTO SUBMITTED BY THE CUSTOMER CONFIRMED THE REPORTED DARKENED, DISCOLORED CANNULAE. IT IS LIKELY THAT THE DARKENING OF THE CANNULAE RESULTED FROM EXPOSURE TO ENVIRONMENTAL FACTORS IN THE PATIENT'S SURROUNDINGS OR FROM THE AGE OF THE MATERIAL. THIS PATTERN IS CONSISTENT WITH PREVIOUSLY-REPORTED INSTANCES OF DARKENED CANNULA. THE ROOT CAUSE OF THE DARKENED CANNULAE CANNOT BE CONCLUSIVELY DETERMINED, BUT APPEARS TO BE CONSISTENT WITH THE CANNULAE DISCOLORATION INVESTIGATED IN PREVIOUSLY WITH OTHER PATIENTS. THE FREEDOM DRIVER SYSTEM OPERATOR MANUAL (F-900012-DE) AND THE FREEDOM DRIVER SYSTEM GUIDEBOOK FOR PATIENTS AND CAREGIVERS (F-900015-DE) INSTRUCT PATIENTS TO EXAMINE THEIR CANNULAE REGULARLY AND TO NOT USE CLEANERS ON THE DRIVELINES, CANNULAE, DRIVERS OR DRIVER ACCESSORIES. USERS ARE TO USE EXTREME CARE WHEN CLEANING THE FREEDOM DRIVER AND DRIVELINES, AND TO WIPE THE DRIVELINES GENTLY WITH A SOFT, CLEAN CLOTH LIGHTLY DAMPENED ONLY WITH WATER. THIS ISSUE WILL CONTINUE TO BE MONITORED AND TRENDED AS PART OF THE CUSTOMER EXPERIENCE PROCESS. SYNCARDIA HAS COMPLETED ITS EVALUATION OF THIS COMPLAINT AND IS CLOSING THIS FILE. (B)(4) FOLLOW-UP REPORT 1.

Description of Event or Problem · 0

THE CUSTOMER, A SYNCARDIA CERTIFIED HOSPITAL, REPORTED THAT THE CANNULA ON THE TAH-T WAS TURNING BROWN-COLORED. THERE WAS NO REPORTED PATIENT IMPACT.

Description of Event or Problem · 0

THE CUSTOMER, A SYNCARDIA CERTIFIED HOSPITAL, REPORTED THAT THE CANNULA ON THE TAH-T WAS TURNING BROWN-COLORED. THERE WAS NO REPORTED PATIENT IMPACT.

Additional Manufacturer Narrative · 1

THE TAH-T CANNULA WILL NOT BE RETURNED TO SYNCARDIA FOR EVALUATION AS THE TAH-T REMAINS IMPLANTED. THE RESULTS OF THE INVESTIGATION WILL BE PROVIDED IN A FOLLOW-UP MDR. (B)(4) INITIAL.

Description of Event or Problem · 1

THE CUSTOMER, A SYNCARDIA CERTIFIED HOSPITAL, REPORTED THAT THE CANNULA ON THE TAH-T WAS TURNING BROWN-COLORED. THERE WAS NO REPORTED PATIENT IMPACT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
102867 SYNCARDIA 70CC TAH-T BIVENTRICULAR REPLACEMENT DEVICE LOZ SYNCARDIA SYSTEMS, LLC 087171

Patients

Seq Age Sex Outcome Treatment
1 55 YR